Related Experiment Video
Updated: May 30, 2026

Closure of a Patent Foramen Ovale (PFO): An Intervention Sequence
Published on: December 23, 2022
Patent foramen ovale in cerebral infarction
J Serena1, M Jiménez-Nieto, Y Silva
1Department of Neurology and Stroke Research Unit. Institut d'Investigaciò Biomèdica de Girona, Spain.
Insights
Patent foramen ovale (PFO) is linked to cryptogenic stroke. This review examines evidence for PFO treatments, including percutaneous closure, to guide management decisions.
Area of Science:
- Cardiology
- Neurology
- Vascular Medicine
Background:
- Patent foramen ovale (PFO) is increasingly associated with cryptogenic stroke.
- Current treatments include antiplatelets, anticoagulation, and PFO closure.
- Treatment decisions are based on clinical factors and shunt characteristics, but evidence is debated.
Purpose of the Study:
- To analyze the role of PFO in cryptogenic stroke.
- To review available evidence for optimal patient management.
- To provide diagnostic and therapeutic recommendations for PFO-related stroke.
Main Methods:
- Literature review of studies on PFO and cryptogenic stroke.
- Analysis of clinical risk factors and shunt characteristics.
- Evaluation of current therapeutic options and their evidence base.
Main Results:
- A strong association exists between PFO and cryptogenic stroke.
- Risk stratification involves patient age, hypercoagulability, stroke history, PFO size, shunt magnitude, and atrial septal aneurysm.
- There is a lack of consensus on optimal treatment, with some approaches lacking clinical evidence.
Conclusions:
- PFO is a significant factor in cryptogenic stroke etiology.
- Evidence-based recommendations are needed for PFO management.
- Further research is required to establish definitive treatment guidelines.
Abstract:
Recent studies support the hypothesis of a close aetiological and pathogenic association between the presence of patent foramen ovale (PFO) and cryptogenic stroke. The therapeutic options currently used in the treatment of these patients range from standard antiaggregation and standard-dose anticoagulation to the percutaneous occlusion of the PFO. The use or recommendation of treatment is based both on clinical risk factors associated with PFO, such as age, detection of states of hypercoagulability and previous history of stroke, and on the risks associated to right-to-left shunt (RLSh) and PFO, such as the size of PFO, magnitude of RLSh and the presence of atrial septal aneurysm (ASA). However, there is currently no consensus regarding the most suitable treatment and it is surprising to observe the widespread use of certain therapeutic approaches which are not supported by clinical evidence. In this revision, we analyse the relevance of PFO in cryptogenic stroke, consider the main evidence available for determining the best management of these patients and make diagnostic and therapeutic management recommendations.
Related Concept Videos
The Arch of Aorta
Encircling the heart, the coronary arteries form a ring-like structure before...
Hemorrhagic Stroke ll: Pathophysiology
Ischemic Stroke ll: Pathophysiology
Cerebral Edema ll: Pathophysiology

